Agonist-dependent activation of CXCR4 and CB2 results in reduced expression of phosphorylated ERK1/2 mediated by CXCR4 and ultimately reduced cancer cell functions such as calcium mobilization and cell chemotaxis (Coke et al., 2016). This evidence concerns the gene CXCR4 and cancer.